Nab-paclitaxel-oxaliplatin-S-1 vs FOLFOX in locally advanced gastric cancer: Efficacy and postoperative disease-free survival prediction

Figure 1 Comparison of disease-free survival and overall survival between the FOLFOX and P-SOX groups. A: Disease-free survival; B: Overall survival. DFS: Disease-free survival; OS: Overall survival.

Figure 2 Least absolute shrinkage and selection operator regression analysis. A: Least absolute shrinkage and selection operator (LASSO) regression with 10-fold cross-validation for selection of the optimal penalty parameter; B: LASSO coefficient profiles of candidate variables as a function of log(λ); C: Coefficients of variables retained by the LASSO-Cox regression model. cTNM: Clinical tumor node metastasis; RECIST: Response evaluation criteria in solid tumors; TRG: Tumor regression grade.

Figure 3 Disease-free survival nomogram. cTNM: Clinical tumor node metastasis; DFS: Disease-free survival; TRG: Tumor regression grade.

Figure 4 Disease-free survival receiver operating characteristic curve. A: 18 months, 24 months, 36 months training set; B: 18 months, 24 months, 36 months validation set. AUC: Area under the curve; CI: Confidence interval.

Figure 5 Decision curve analysis of the nomogram for predicting disease-free survival. A: 18-month training set; B: 24-month training set; C: 36-month training set; D: 18-month validation set; E: 24-month validation set; F: 36-month validation set.

Figure 6 Calibration curves of the nomogram for predicting disease-free survival. A: 18-month training set; B: 24-month training set; C: 36-month training set; D: 18-month validation set; E: 24-month validation set; F: 36-month validation set. AUC: Area under the curve.